CMPS News and Press, COMPASS Pathways Plc

EHang Holdings Limited (EH) is expected to report $-0.06 for Q4 2025 McEwen Inc. (MUX) is expected to report $0.25 for Q4 2025 Hannover Ruck SE ADR - Level I (HVRRY) is expected to report $1.03 for Q4 2025 VAALCO Energy Inc. (EGY) is expected to report $0.02 for Q4 2025 Full Truck...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Stifel 2026 Virtual CNS Forum, from March 17-18, 2026, and will participate in a fireside chat on Ma...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions Canada NewsWire Issued on behalf of Cybin D/B/A Helus Pharma USANewsGroup.com News Commentary VANCOUVER, BC , March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approachi...

2026-03-09 07:10:16 ET Cathie Wood’s ARK Invest snapped up shares in e-commerce, fintech and next-generation aviation companies while trimming positions in satellite communications, semiconductors and streaming firms in the week through March 6.... Read the full article on Seek...

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Canada NewsWire Issued on behalf of Helus Pharma VANCOUVER, BC , Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 ...

2026-02-26 07:37:16 ET More on COMPASS Pathways ADS COMPASS Pathways plc (CMPS) Discusses Positive Phase III Results for COMP360 in Treatment-Resistant Depression Trials Transcript Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot COMPASS Pathway...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were issued on January 13, 2025, for proceeds of approximately $200 million. Upon exercise of these outsta...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-02-24 09:35:33 ET Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value Catalysts New York, NY –February 24, 2026 – Market News Updates News Commentary – Mental health disorders—in...